These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 33759204)
41. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system. Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662 [TBL] [Abstract][Full Text] [Related]
42. Commonality between BCS and TCS. Shah VP; Rădulescu FŞ; Miron DS; Yacobi A Int J Pharm; 2016 Jul; 509(1-2):35-40. PubMed ID: 27208656 [TBL] [Abstract][Full Text] [Related]
43. BCS-based biowaivers: Extension to paediatrics. Martir J; Flanagan T; Mann J; Fotaki N Eur J Pharm Sci; 2020 Dec; 155():105549. PubMed ID: 32941998 [TBL] [Abstract][Full Text] [Related]
44. Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis. Li X; Yang Y; Zhang Y; Wu C; Jiang Q; Wang W; Li H; Li J; Luo C; Wu W; Wang Y; Zhang T Mol Pharm; 2019 Sep; 16(9):3780-3790. PubMed ID: 31398041 [TBL] [Abstract][Full Text] [Related]
45. Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate. Charoo NA; Shamsher AA; Lian LY; Abrahamsson B; Cristofoletti R; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J J Pharm Sci; 2014 Feb; 103(2):378-91. PubMed ID: 24382794 [TBL] [Abstract][Full Text] [Related]
47. ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Bransford P; Cook J; Gupta M; Haertter S; He H; Ju R; Kanodia J; Lennernäs H; Lindley D; Polli JE; Wenning L; Wu Y Mol Pharm; 2020 Feb; 17(2):361-372. PubMed ID: 31846335 [TBL] [Abstract][Full Text] [Related]
50. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study. Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498 [TBL] [Abstract][Full Text] [Related]
51. The Discriminatory Power of the BCS-Based Biowaiver: A Retrospective With Focus on Essential Medicines. Hofsäss MA; Dressman JB J Pharm Sci; 2019 Sep; 108(9):2824-2837. PubMed ID: 31059698 [TBL] [Abstract][Full Text] [Related]
52. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Yu LX; Amidon GL; Polli JE; Zhao H; Mehta MU; Conner DP; Shah VP; Lesko LJ; Chen ML; Lee VH; Hussain AS Pharm Res; 2002 Jul; 19(7):921-5. PubMed ID: 12180542 [TBL] [Abstract][Full Text] [Related]
53. Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations. Ono A; Sugano K Eur J Pharm Sci; 2014 Nov; 64():37-43. PubMed ID: 25151946 [TBL] [Abstract][Full Text] [Related]
54. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Lindenberg M; Kopp S; Dressman JB Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954 [TBL] [Abstract][Full Text] [Related]
55. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development. Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742 [TBL] [Abstract][Full Text] [Related]
57. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development. Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248 [TBL] [Abstract][Full Text] [Related]
58. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space. Bhattiprolu AK; Kollipara S; Ahmed T; Boddu R; Chachad S J Pharm Sci; 2022 Dec; 111(12):3397-3410. PubMed ID: 36096285 [TBL] [Abstract][Full Text] [Related]